Opinion|Videos|November 17, 2026

HER2 Mutation and Overexpression in Lung Cancer

Benjamin Levy, MD, explains that human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer take 3 forms: mutation, overexpression, and amplification, with amplification still lacking a treatment indication.

Benjamin Levy, MD, explains that human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer take 3 forms: mutation, overexpression, and amplification, with amplification still lacking a treatment indication. His team performs upfront next-generation sequencing (NGS) of tissue and blood to identify HER2 exon 20 mutations, which he treats with the oral tyrosine kinase inhibitors zongertinib or sevabertinib or with the antibody-drug conjugate trastuzumab deruxtecan. HER2 overexpression at immunohistochemistry (IHC) 3+ qualifies patients for trastuzumab deruxtecan under a pan-tumor approval limited to later lines. Because clinicians do not yet know whether HER2 expression changes over the course of treatment, Dr. Levy adds HER2 IHC to upfront testing and applies the result at progression, an approach he acknowledges rests on limited evidence. He notes that about 20% of his patients lack enough tissue for expanded NGS. Dr. Levy describes HER2 as undruggable in lung cancer for 15 years before recent progress.


Related to this article